Prosecution Insights
Last updated: October 02, 2026
Application No. 18/589,673

COMPOSITIONS AND METHODS FOR TREATING PAIN IN ANIMALS

Final Rejection §112
Filed
Feb 28, 2024
Priority
Feb 28, 2023 — provisional 63/487,479
Examiner
HUI, SAN MING R
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
North Carolina State University
OA Round
2 (Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
784 granted / 1317 resolved
-0.5% vs TC avg
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
44 currently pending
Career history
1352
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
47.1%
+7.1% vs TC avg
§102
7.5%
-32.5% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1317 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendments filed 6/1/2026 have been entered. Claims 1-11 and 14-20 are pending. The outstanding rejection under 35 USC 103a is withdrawn in view of the amendments filed 6/1/2026. A new ground of rejection is set forth due to the amendments filed 6/1/2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 11 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 11 recites the limitation "analgesic" in line 1. There is insufficient antecedent basis for this limitation in the claim. Allowable Subject Matter Claims 1-10, 14-20 are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAN MING R HUI whose telephone number is (571)272-0626. The examiner can normally be reached Mon - Fri 9:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAN MING R HUI/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Feb 28, 2024
Application Filed
Mar 24, 2026
Non-Final Rejection mailed — §112
Jun 01, 2026
Response Filed
Aug 12, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734179
PROGESTERONE FORMULATION TO TRIGGER OVULATION AND PROVIDE LUTEAL PHASE SUPPORT
4y 2m to grant Granted Sep 15, 2026
Patent 12735448
CRYSTAL FORM OF 3-HYDROXY-5-PREGNANE-20-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 1m to grant Granted Sep 15, 2026
Patent 12723047
HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
3y 4m to grant Granted Sep 01, 2026
Patent 12714104
COMPOSITION FOR CONTROLLING FLYING PEST INSECTS
2y 11m to grant Granted Aug 25, 2026
Patent 12708628
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MOTION SICKNESS AND EMESIS
2y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
80%
With Interview (+20.1%)
2y 11m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1317 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month